Novel non-ATP competitive small molecules targeting the CK2 α/β interface
Open Access
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (11) , 3016-3020
Abstract
No abstract availableKeywords
Funding Information
- European Research Council
- Wellcome Trust Strategic (090340/Z/09/Z)
- PATHFINDER (107714/Z/15/Z)
- Engineering and Physical Sciences Research Council
- Biotechnology and Biological Sciences Research Council
- Medical Research Council
- Royal Society
This publication has 23 references indexed in Scilit:
- CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic TargetPharmaceuticals, 2017
- The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignanciesFrontiers in Pharmacology, 2015
- CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor EfficacyCancer Research, 2010
- Emergence of protein kinase CK2 as a key target in cancer therapyBioFactors, 2010
- New Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic BoxChemistry & Biology, 2009
- Protein kinase CK2 – A key suppressor of apoptosisAdvances in Enzyme Regulation, 2008
- Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA)Biochemical Journal, 2003
- Joining the cell survival squad: an emerging role for protein kinase CK2Trends in Cell Biology, 2002
- Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cellsThe International Journal of Biochemistry & Cell Biology, 1999
- Protein kinase CK2 and its role in cellular proliferation, development and pathologyElectrophoresis, 1999